搜索优化
English
全部
搜索
图片
视频
地图
资讯
Copilot
更多
购物
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
最新
最佳匹配
资讯
腾讯网
1 小时
FDA再批准礼来阿尔茨海默病药物!
礼来(Eli Lilly and Company)今日宣布,美国FDA已批准Kisunla(donanemab)的标签更新,新增推荐的滴定给药方案。Kisunla为一款每月一次的靶向淀粉样蛋白疗法,适用于早期阿尔茨海默病(AD)患者,包括轻度认知障碍 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Central Texas flash floods
X CEO resigns
Death ruled a homicide
Announces anti-graft plan
Barbie with Type 1 diabetes
'Click-to-cancel' blocked
Trump admin sues California
Midair collision in Manitoba
American Kennel Club sued
Won't revive immigration law
Cracker sandwiches recalled
Cause of death revealed
Turkish court bans Grok
Ex-doctor refuses to answer
Russia batters Ukraine
Guatemala earthquakes
Hits $4 trillion market cap
Los Angeles joins ACLU suit
Greece blocks asylum claims
Christian Horner sacked
New Mexico flooding
Invests in EssilorLuxottica
To buy Verona Pharma
Harvard faces subpoenas
Sinner defeats Shelton
5-yr extension w/ Thunder
Former Gov. DiPrete dies
Cyclist LeMond honored
14th Wimbledon semifinal
Confirmed to lead FAA
US sanctions UN official
反馈